KMT2A-MAML2 fusion molecules and uses thereof
AssigneeFoundation Medicine, Inc.
InventorErik Williams
Life of this patent
Estimating the term…
Abstract
The present disclosure provides KMT2A-MAML2 fusion nucleic acid molecules, and KMT2A-MAML2 fusion polypeptides, as well as methods, kits and reagents for detecting such KMT2A-MAML2 fusion nucleic acid molecules and KMT2A-MAML2 fusion polypeptides. The disclosure also provides methods for evaluating, identifying, assessing, and/or treating an individual having a cancer, such an epithelial neoplasm or a thymoma.
Claims36
A method of treating a thymoma in an individual, comprising administering to the individual an effective amount of an anti-cancer therapy, wherein the thymoma comprises a KMT2A-MAML2 fusion nucleic acid molecule or a KMT2A-MAML2 fusion polypeptide;
- wherein the anti-cancer therapy is an agent that inhibits activity or expression of the KMT2A-MAML2 polypeptide, a NOTCH pathway inhibitor, or an agent that inhibits activity or expression of epidermal growth factor receptor (EGFR).
A method of treating a thymoma in an individual, comprising, responsive to knowledge of a KMT2A-MAML2 fusion nucleic acid molecule or of a KMT2A-MAML2 fusion polypeptide in a sample from the individual, administering to the individual an effective amount of an anti-cancer therapy;
- wherein the anti-cancer therapy is an agent that inhibits activity or expression of the KMT2A-MAML2 polypeptide, a NOTCH pathway inhibitor, or an agent that inhibits activity or expression of epidermal growth factor receptor (EGFR).
A method of treating a thymoma in an individual, comprising:
- (a) acquiring knowledge of a KMT2A-MAML2 fusion nucleic acid molecule or a KMT2A-MAML2 fusion polypeptide in a sample from the individual;
- and
- (b) administering to the individual an effective amount of an anti-cancer therapy, wherein the anti-cancer therapy is an agent that inhibits activity or expression of the KMT2A-MAML2 polypeptide, a NOTCH pathway inhibitor, or an agent that inhibits activity or expression of epidermal growth factor receptor (EGFR).
Dependencies are inferred from the claim text.